List of Excipients in Branded Drug ALINIA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
LUPIN PHARMACEUTICALS INC	ALINIA	nitazoxanide	27437-106	ANHYDROUS CITRIC ACID
LUPIN PHARMACEUTICALS INC	ALINIA	nitazoxanide	27437-106	CARBOXYMETHYLCELLULOSE SODIUM
LUPIN PHARMACEUTICALS INC	ALINIA	nitazoxanide	27437-106	CELLULOSE, MICROCRYSTALLINE
LUPIN PHARMACEUTICALS INC	ALINIA	nitazoxanide	27437-106	FD&C RED NO. 40
LUPIN PHARMACEUTICALS INC	ALINIA	nitazoxanide	27437-106	MALTODEXTRIN
LUPIN PHARMACEUTICALS INC	ALINIA	nitazoxanide	27437-106	MODIFIED CORN STARCH
LUPIN PHARMACEUTICALS INC	ALINIA	nitazoxanide	27437-106	SODIUM BENZOATE

ALINIA Excipient Strategy and Commercial Opportunities for Nitazoxanide

Last updated: August 3, 2026

Alinia, the branded nitazoxanide product from Romark, has limited composition-of-matter protection and competes in a generic small-molecule market. The strongest commercial opportunities are therefore in pediatric taste masking, ready-to-use oral suspension, unit-dose packaging, improved dispersibility, and differentiated global formulations rather than in a new active ingredient.

The core excipient strategy should preserve nitazoxanide’s dose uniformity and chemical stability while improving palatability, reconstitution, portability, and manufacturing efficiency. Generic entry risk is high for standard nitazoxanide tablets and conventional oral suspension. A defensible formulation program would need a measurable performance advantage and claims directed to composition, dissolution, stability, delivery, or patient adherence.

What is Alinia and which formulations are commercially relevant?

Alinia contains nitazoxanide, an antiprotozoal agent. The FDA-approved products are a 500 mg tablet and a 100 mg/5 mL oral suspension. The labeled indications cover diarrhea caused by Giardia lamblia or Cryptosporidium parvum in adults and children aged at least one year, with dosage dependent on age and formulation [1].

Product	Strength	Dosage form	Principal commercial segment	Strategic issue
Alinia tablet	500 mg	Immediate-release tablet	Adults and older pediatric patients	Direct generic substitution
Alinia oral suspension	100 mg/5 mL	Powder for reconstitution	Children aged 1-11 years	Taste, reconstitution, dosing accuracy
Nitazoxanide generic tablets	Commonly 500 mg	Immediate-release tablet	Pharmacy and institutional channels	Price competition
Nitazoxanide generic suspension	Varies by manufacturer	Powder or liquid suspension	Pediatric and global markets	Stability and palatability differentiation

The oral suspension has greater formulation value because pediatric treatment creates barriers that are not solved by active-ingredient equivalence alone. Taste, aftertaste, sedimentation, syringe compatibility, storage, and caregiver compliance influence product selection.

What excipients are used in Alinia formulations?

FDA labeling identifies different excipient systems for the tablet and oral suspension. The tablet uses conventional direct-compression or wet-granulation excipients, while the suspension uses a sugar-based, polymer-thickened system designed for reconstitution and dose uniformity [1].

Alinia tablet excipient strategy

The tablet formulation includes excipient classes such as:

• Pregelatinized starch for binding and disintegration
• Microcrystalline cellulose for compressibility and bulk
• Croscarmellose sodium for rapid tablet breakup
• Magnesium stearate as a lubricant
• Hypromellose and related coating materials
• Talc and titanium dioxide in the film-coating system

This is a conventional immediate-release platform. Its principal advantages are low manufacturing complexity, established regulatory precedent, and broad availability of excipient suppliers. Its commercial weakness is limited differentiation. A generic manufacturer can usually reproduce the functional performance with alternative grades or equivalent excipient combinations.

Alinia oral suspension excipient strategy

The oral suspension uses a different design logic. The labeled system includes sucrose, xanthan gum, sodium benzoate, citric acid, sodium citrate, silicon dioxide, and flavoring components [1].

Functional requirement	Likely excipient role
Palatability	Sucrose and flavor system
Suspending behavior	Xanthan gum
Microbial control	Sodium benzoate
pH control	Citric acid and sodium citrate
Flow and powder handling	Silicon dioxide
Dose uniformity after reconstitution	Polymer viscosity and particle wetting
Caregiver acceptance	Flavor, mouthfeel, aftertaste control

The principal technical risk is the interaction between flavor, polymer viscosity, preservative concentration, pH, and nitazoxanide particle behavior. Increasing viscosity can improve suspension uniformity but may reduce pourability and oral-syringe dosing accuracy. Increasing sweetener may improve taste but can increase powder bulk, hygroscopicity, and microbial-control requirements.

What excipient opportunities exist for an improved nitazoxanide product?

The highest-value opportunities are concentrated in the pediatric liquid product.

Taste masking and aftertaste reduction

Nitazoxanide can be difficult to formulate for children because the active ingredient has limited aqueous solubility and may produce a persistent taste when dispersed in the mouth. Commercial approaches include:

• Polymer coating of nitazoxanide particles
• Ion-exchange resin complexes
• Lipid or wax-based microparticles
• Cyclodextrin complexes
• pH-controlled flavor systems
• Multi-layer flavor masking
• Sweetener combinations using sucrose, sucralose, acesulfame potassium, or polyols

A patentable formulation would need more than the presence of a known sweetener. Stronger claims would connect the excipient system to a measurable result, such as reduced bitterness, lower particle deposition in the oral cavity, improved reconstitution, or equivalent bioavailability.

Ready-to-use liquid formulations

A ready-to-use suspension could remove the reconstitution step and reduce dosing errors. The principal obstacles are chemical stability, preservative performance, sedimentation, container compatibility, and shipping weight.

Commercial opportunities include:

• Low-water-activity suspensions
• Concentrated liquid products administered in smaller volumes
• Dual-chamber packaging
• Unit-dose oral syringes
• Sachets that reconstitute to a fixed volume
• Bottle systems with integrated dosing adapters

A ready-to-use product may command a premium in pediatric clinics, hospitals, travel medicine, and markets where caregivers have limited access to calibrated measuring devices.

Lower-sugar and sugar-free products

The existing suspension’s sucrose-based approach is familiar and effective for taste, but a lower-sugar or sugar-free formulation could address dental, metabolic, and institutional concerns. Potential excipient systems include polyols, high-intensity sweeteners, and structured flavor combinations.

The formulation must control:

• Osmolality
• Gastrointestinal tolerance
• Preservative efficacy
• Viscosity
• Sweetener aftertaste
• Stability across hot and humid distribution conditions

A sugar-free product is commercially useful only if taste remains acceptable. Pediatric palatability testing should be treated as a development gate rather than a post-formulation marketing exercise.

How strong is the patent estate for Alinia and nitazoxanide formulations?

Nitazoxanide is an established small molecule, so the original active-ingredient and early product-protection period has largely elapsed. Standard 500 mg immediate-release tablets have high generic-entry exposure. The strongest remaining intellectual-property opportunity is likely to be a new formulation, delivery system, use, or manufacturing process rather than the active ingredient itself.

IP category	Strategic strength	Generic-entry effect
Nitazoxanide composition of matter	Low for new U.S. products	Does not materially block standard generics
Conventional 500 mg tablet	Low	ANDA substitution risk is high
Conventional powder suspension	Low to moderate	Depends on ANDA availability and market access
Taste-masked particles	Moderate to high if technically narrow	May support differentiated product claims
Ready-to-use suspension	Moderate	Requires stability and bioequivalence support
Pediatric dosing device	Low alone, moderate with formulation integration	Can support packaging or device claims
Manufacturing process	Moderate if it reduces impurities or improves particle attributes	May create process-barrier or licensing value
New method of use	Variable	Depends on claim scope and enforceability

Patent claims directed only to excipient identity are generally vulnerable if the excipient is already used in pharmaceutical products. Stronger claims specify concentration ranges, particle-size distributions, coating thickness, dissolution behavior, stability thresholds, or a defined pharmacokinetic profile.

When does Alinia lose exclusivity and what is the generic-entry risk?

Alinia’s principal exclusivity risk is generic substitution, not biosimilar competition. Nitazoxanide is a chemically synthesized small molecule and is not regulated through the biologic licensing pathway.

The original Alinia approvals date to the early 2000s. Any original regulatory exclusivity associated with those approvals has expired. The product therefore depends on brand prescribing, supply reliability, formulation convenience, and market-specific commercial execution rather than remaining FDA exclusivity.

Paragraph IV challenges and Orange Book status

A Paragraph IV certification can challenge an unexpired patent listed for an NDA product. For an established nitazoxanide product, the commercial significance of a Paragraph IV filing depends on whether a live Orange Book-listed patent covers the proposed generic product and whether the patent holder brings litigation within the statutory period.

The relevant regulatory records are:

• Alinia NDA 021497
• FDA Orange Book patent listings for the applicable NDA
• FDA Approved Drug Products with Therapeutic Equivalence Evaluations
• ANDA approvals for nitazoxanide tablets or suspension
• Any district-court or Federal Circuit litigation involving listed patents

A generic tablet does not automatically eliminate the commercial value of the branded suspension. Dosage form, age indication, device, flavor, and supply reliability can segment the market. Conversely, a generic suspension with acceptable taste and equivalent dosing could materially reduce branded revenue.

What FDA regulatory pathway applies to an improved Alinia formulation?

A generic version of an existing dosage form would normally use an ANDA, subject to bioequivalence and pharmaceutical-equivalence requirements. A materially different formulation may require a 505(b)(2) application if the sponsor relies partly on FDA findings for nitazoxanide but introduces a new formulation, delivery system, strength, or route [2].

Product concept	Likely pathway	Main evidence burden
Equivalent 500 mg tablet	ANDA	Pharmaceutical equivalence and bioequivalence
Equivalent powder suspension	ANDA	Bioequivalence, reconstitution, stability
New taste-masked suspension	505(b)(2) or ANDA if equivalence is demonstrated	Formulation characterization and comparative performance
Ready-to-use suspension	505(b)(2) likely	Stability, microbiology, bioavailability
New pediatric delivery device	ANDA or 505(b)(2), depending on formulation changes	Device compatibility and dosing accuracy
New indication	505(b)(2) or supplemental NDA	Clinical and regulatory support for the indication

FDA’s Inactive Ingredient Database can support excipient selection, but prior use of an excipient does not establish approval for every concentration, route, dosage form, or patient population [3]. Sponsors must also address preservative effectiveness, elemental impurities, nitrosamine risk where relevant, extractables and leachables, and container-closure integrity.

Which commercial opportunities are most attractive?

Pediatric specialty product

A premium pediatric product combining taste masking, a calibrated oral syringe, and a low-volume dose has the clearest differentiation path. The product could target pediatricians, emergency departments, infectious-disease clinics, and caregivers.

The commercial thesis depends on:

• Demonstrated acceptance in children
• Reduced dosing errors
• Stable shelf life under non-refrigerated conditions
• Simple reconstitution or no reconstitution
• Competitive acquisition cost for pharmacies and hospitals

Global tropical-disease markets

Nitazoxanide is relevant in markets where Giardia and Cryptosporidium treatment is needed, particularly where waterborne infection and pediatric diarrheal disease remain significant. The formulation must tolerate heat, humidity, and irregular distribution. Sachets, dispersible tablets, and small-volume suspensions may be more commercially suitable than a U.S.-style bottle.

Local regulatory requirements, excipient restrictions, sugar policies, and procurement tenders will determine market access. Low-cost manufacturing and packaging efficiency may matter more than premium flavor in public-sector channels.

Institutional and travel medicine products

Unit-dose sachets, oral syringes, and compact dispersible tablets could address hospitals, travel clinics, military deployments, and humanitarian supply channels. These formats reduce bottle handling and may simplify inventory management.

Licensing opportunities

A formulation company could license:

• Taste-masking technology
• Nitazoxanide microparticles
• Ready-to-use suspension technology
• Stabilized oral liquid platforms
• Single-dose packaging
• Pediatric adherence data
• Improved manufacturing processes

The most valuable licensing package would combine composition claims with comparative human or pediatric palatability data. An excipient list alone is unlikely to command a significant royalty stream.

How does Alinia compare with competing anti-infective products?

Attribute	Alinia/nitazoxanide	Metronidazole	Tinidazole	Generic albendazole
Primary formulation opportunity	Pediatric suspension and taste masking	Oral liquids and tablets	Tablets and simplified dosing	Chewable and pediatric products
Generic pressure	High	High	High	High
Biosimilar risk	None	None	None	None
Main differentiation lever	Palatability and dosing convenience	Indication breadth and cost	Short-course dosing	Broad antiparasitic positioning
Excipient value	Moderate to high in pediatric liquid	Moderate	Moderate	High in chewable formats
Patent strategy	New delivery and formulation	Formulation and use claims	Formulation and use claims	Pediatric and combination products

Alinia’s competitive advantage is most defensible where nitazoxanide’s existing clinical positioning is combined with a superior pediatric product experience. A standard tablet is unlikely to support durable premium pricing.

What manufacturing and IP barriers affect a new product?

The principal manufacturing barriers are particle engineering, uniform coating, suspension rheology, taste-mask robustness, and scale-up reproducibility. Nitazoxanide’s low solubility can complicate dissolution testing and bioequivalence. A formulation that performs well at laboratory scale may fail during commercial mixing because of agglomeration, altered viscosity, or nonuniform flavor distribution.

A development program should establish:

1. Active-particle size and morphology controls.
2. Coating uniformity and release specifications.
3. Reconstitution time and sedimentation limits.
4. Oral-syringe dose accuracy.
5. Preservative effectiveness after reconstitution.
6. Stability under accelerated and high-humidity conditions.
7. Comparative dissolution and pharmacokinetics.
8. Human palatability data.
9. Freedom-to-operate analysis for coating, resin, lipid, and packaging technologies.

What revenue exposure and launch scenarios exist?

Romark is privately held, and product-level Alinia revenue is not consistently disclosed in public-company filings. Revenue exposure should therefore be modeled from prescription volume, net price, payer mix, and generic substitution rather than from a verified public product-revenue figure.

Scenario	Market effect	Commercial implication
Standard generic tablet launch	Rapid price erosion in adult segment	Brand shifts toward suspension and institutional channels
Generic suspension launch	Greater pediatric erosion	Taste and device differentiation become critical
Premium taste-masked product	Partial price insulation	Requires clinical or adherence evidence
Ready-to-use product	Potential premium and channel expansion	Higher packaging and stability costs
Global low-cost launch	Volume growth with lower margins	Requires efficient manufacturing and tender strategy

Key Takeaways

• Alinia is a nitazoxanide product with tablet and oral-suspension presentations.
• Standard tablet composition has limited differentiation and high generic-entry exposure.
• The most attractive excipient opportunity is pediatric taste masking combined with dosing convenience.
• Ready-to-use, low-volume, sugar-reduced, and unit-dose formats offer additional commercial paths.
• A new formulation would likely require an ANDA only if it remains pharmaceutically equivalent; materially different products may require a 505(b)(2) application.
• Nitazoxanide has no biosimilar risk because it is a small-molecule drug.
• Strong formulation patents should claim measurable performance, not merely the use of a familiar excipient.
• Product-level Alinia revenue is not publicly disclosed with sufficient consistency for a reliable standalone estimate.
• The most defensible licensing asset would combine formulation IP, manufacturing know-how, and pediatric palatability evidence.

FAQs

Can a generic manufacturer copy Alinia’s excipients?

A generic manufacturer may use the same or functionally equivalent excipients if the product meets FDA requirements for pharmaceutical equivalence, bioequivalence, quality, and labeling. Exact excipient copying is not required.

Is nitazoxanide suitable for a chewable tablet?

Yes, but the formulation would need effective taste masking, sufficient mechanical strength, rapid disintegration, and acceptable dose uniformity. A chewable product could be more commercially useful for pediatric patients than a conventional tablet.

Can a taste-masked nitazoxanide product receive new exclusivity?

Potentially. A sufficiently novel formulation approved through an applicable regulatory pathway may qualify for patent protection and, depending on the regulatory basis, limited statutory exclusivity. The scope depends on the approved changes and claim construction.

What excipients are most important for nitazoxanide suspension stability?

The critical system includes a suspending polymer, preservative, buffer, sweetener, flavor, and powder-flow aid. Their concentrations must be optimized together because viscosity, pH, microbial control, and palatability interact.

Is an Alinia oral suspension more defensible than the tablet?

Yes. The suspension offers more opportunities for differentiated claims covering taste masking, particle engineering, reconstitution, stability, dosing devices, and ready-to-use delivery. The tablet is easier for generic manufacturers to reproduce.

References

1. U.S. Food and Drug Administration. (2023). Alinia (nitazoxanide) tablets and oral suspension prescribing information.
2. U.S. Food and Drug Administration. (2024). 505(b)(2) applications.
3. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.